This Medudy Expert Opinion with Prof. Sherko Kümmel is a video tutorial for physicians on the topic of "Treatment of metastatic triple-negative breast cancer (TNBC)".
The content first highlights the historical situation in 2018, when the prognosis for high-risk tumor biology was very poor and the median overall survival was only 12 to 15 months. The tutorial presents current therapeutic approaches, including immunotherapy, PARP inhibitors and antibody-drug conjugates (ADCs). It goes into detail about the target molecules and the biomarker diagnostics required in each case, such as PD-L1 status for immunotherapy or germline BRCA mutations for PARP inhibitors. Finally, clinical data and response rates are discussed in the context of these versatile treatment strategies.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of Gilead Science and MSD.
At the end of this training you will know:
- the high biological heterogeneity of TNBC and the defined gene expression subtypes
- current therapeutic strategies such as immunotherapy, PARP inhibitors and antibody drug conjugates (ADCs)
- the importance of specific biomarkers (e.g. PD-L1, gBRCA mutations) for the selection of targeted therapy approaches.
